Elanco Animal Health Inc (NYSE:ELAN) has a beta value of 1.68 and has seen 7.18 million shares traded in the last trading session. The company, currently valued at $6.67B, closed the last trade at $13.44 per share which meant it lost -$0.08 on the day or -0.59% during that session. The ELAN stock price is -39.88% off its 52-week high price of $18.80 and 40.33% above the 52-week low of $8.02.
The consensus among analysts is that Elanco Animal Health Inc (ELAN) is Buy stock at the moment, with a recommendation rating of 1.87. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 5 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.2.
Elanco Animal Health Inc (NYSE:ELAN) trade information
Sporting -0.59% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ELAN stock price touched $13.44 or saw a rise of 5.35%. Year-to-date, Elanco Animal Health Inc shares have moved 10.98%, while the 5-day performance has seen it change 6.08%. Over the past 30 days, the shares of Elanco Animal Health Inc (NYSE:ELAN) have changed 41.77%.
Wall Street analysts have a consensus price target for the stock at $12, which means that the shares’ value could drop -12.0% from current levels. The projected low price target is $11.0 while the price target rests at a high of $18.0. In that case, then, we find that the current price level is -33.93% off the targeted high while a plunge would see the stock lose 18.15% from current levels.
Elanco Animal Health Inc (ELAN) estimates and forecasts
The company’s shares have gained 0.37% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 2.13%.
7 analysts offering their estimates for the company have set an average revenue estimate of 1.19B for the current quarter. 7 have an estimated revenue figure of 1.08B for the next ending quarter. Year-ago sales stood 1.18B and 1.03B respectively for this quarter and the next, and analysts expect sales will grow by 0.16% for the current quarter and 2.13% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 29.95% over the past 5 years. Earnings growth for 2025 is a modest -7.38% while over the next 5 years, the company’s earnings are expected to increase by 6.04%.
ELAN Dividends
Elanco Animal Health Inc is expected to release its next earnings report in July this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Elanco Animal Health Inc (NYSE:ELAN)’s Major holders
The top two institutional holders are DODGE & COX with over 83.58 million shares worth more than $1.21 billion. As of 2024-06-30, DODGE & COX held 16.9128% of shares outstanding.
The other major institutional holder is PRIMECAP MANAGEMENT CO/CA/, with the holding of over 52.8 million shares as of 2024-06-30. The firm’s total holdings are worth over $761.94 million and represent 10.6845% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Dodge & Cox Funds-Dodge & Cox Stock Fund and VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund . As of Mar 31, 2025 , the former fund manager holds about 11.14% shares in the company for having 55.34 shares of worth $743.79 million while later fund manager owns 18.91 shares of worth $254.2 million as of Mar 31, 2025 , which makes it owner of about 3.81% of company’s outstanding stock.
